Diltiazem preserves hepatic gluconeogenesis following hemorrhagic shock

E R Geller1, L D Higgins, N Drourr

  • 1Department of Surgery, School of Medicine, State University of New York, Stony Brook 11794-8191.

The Journal of Trauma
|November 1, 1993
PubMed

Insights

Diltiazem resuscitation improved hepatic gluconeogenesis in rats experiencing hemorrhagic shock. This intervention enhanced the liver's glucose production capacity, even after prolonged shock, suggesting a potential therapeutic benefit.

Area of Science:

  • Physiology
  • Biochemistry
  • Pharmacology

Background:

  • Prolonged hemorrhagic shock leads to metabolic dysfunction, including impaired hepatic gluconeogenesis and altered glucose homeostasis.
  • Previous research suggests diltiazem may improve survival in hemorrhagic shock models.
  • Understanding the impact of diltiazem on hepatic gluconeogenesis during shock is crucial for developing effective resuscitation strategies.

Purpose of the Study:

  • To investigate the effect of diltiazem-containing resuscitation on hepatic gluconeogenesis during early and late phases of hemorrhagic shock in a rat model.
  • To assess the impact of diltiazem on the liver's capacity to produce glucose following hemorrhagic shock and resuscitation.

Main Methods:

  • Male Sprague-Dawley rats were subjected to 30 or 120 minutes of hemorrhagic shock.
  • Resuscitation was performed using lactated Ringer's (LR) solution with or without diltiazem (DZ).
  • In situ liver perfusion was utilized to measure hepatic gluconeogenesis following resuscitation.

Main Results:

  • Diltiazem resuscitation significantly increased hepatic glucose production in both early (30 min) and late (120 min) phases of hemorrhagic shock compared to controls.
  • Treated rats demonstrated an improved gluconeogenic response to lactate and pyruvate substrate.
  • Serum glucose concentration and portal venous flow did not differ significantly between groups.

Conclusions:

  • Resuscitation with diltiazem enhances hepatic gluconeogenesis during and after prolonged hemorrhagic shock in rats.
  • Diltiazem may mitigate the metabolic derangements associated with hemorrhagic shock by supporting liver glucose production.
  • These findings suggest a potential role for diltiazem in improving metabolic recovery following severe hemorrhage.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...